During the high profile JPMorgan Healthcare Conference, Motley Fool health care bureau chief Brenton Flynn took a moment to look back at some of the interesting things he observed. In this segment of the video, he discusses a prostate-cancer-focused biotech Medivation (NASDAQ: MDVN ) and its presentation -- and three potential share price catalysts.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.